BPC-157: benefits, safety,
and what the research shows.

Short answer

BPC-157 is a synthetic peptide — fifteen amino acids derived from a protein found in gastric juice — studied for tendon, ligament, muscle and digestive-tract repair. Its name stands for Body Protection Compound. The strongest evidence is preclinical (animal and cell studies); human research is limited, and it is not an FDA-approved drug.

Evidence and status

BPC-157 is not FDA-approved for any use, and compounded versions are not FDA-approved. The strongest support comes from animal and laboratory research; human data is limited to small studies. Everything below is written in that light — described mechanisms and reported patterns, not promises.

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids derived from a protein found in human gastric juice. "BPC" stands for Body Protection Compound.

It is often described as stable in gastric acid, which is why oral administration gets discussed alongside injection. In research settings it is studied as a systemic and local repair signal.

What does the BPC-157 peptide do?

This is the most-asked question, and the honest version is about mechanisms, not guarantees. In animal and cell studies, BPC-157 has been described:

• promoting angiogenesis — the growth of new blood vessels into tissue;
• increasing fibroblast migration — the cells that lay down new collagen;
• improving cell survival under oxidative stress via the FAK-paxillin pathway;
• upregulating the growth-hormone receptor in tendon fibroblasts.

Interest centres on tissues that are slow to heal — tendon, ligament and the gut lining — because those are the areas where the preclinical signal is most consistent.

How does BPC-157 work?

The proposed throughline is blood supply. Tendon and ligament heal slowly in large part because they are poorly vascularised — they get very little blood, so repair materials arrive slowly. Much of the BPC-157 research interest is in whether it supports the delivery side of repair: new vessels, cell migration, and survival of the cells doing the rebuilding. That is a plausible mechanism. It is not, on its own, proof of a clinical result.

What has human research found?

Less than the internet implies. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found favourable animal safety and pharmacokinetic data, with human research limited to small pilot studies. There are no large published randomised controlled trials establishing efficacy for tendon or ligament injury in people.

Is BPC-157 hard on your liver?

There is no established human evidence that BPC-157 damages the liver, and animal work has not flagged the liver as a primary concern. But the caveats are real: human safety data is limited, there are no long-term human safety studies, and purity varies enormously between sources — an unregulated product can contain things the label doesn't. That last point is usually the bigger risk than the peptide itself, which is why blood work and clinician oversight matter.

Dosage: can you take BPC-157 every day?

Reported use patterns describe daily protocols run over short cycles of several weeks — but frequency, dose and duration are not standardised and not FDA-approved, and reported numbers vary widely between sources. Nothing here is a dosing recommendation. This is exactly the kind of decision that belongs with a licensed clinician who can look at the actual injury, your history and your blood work — not a checkout page.

Does BPC-157 really work?

The fair answer: the preclinical evidence is genuinely interesting, but mechanism is not outcome. A compound can do everything above in a rat and still not change anything meaningful in a person. Human research hasn't closed that gap yet. If someone tells you it's proven, they're ahead of the science. It is studied — not proven.

Making sense of before-and-after stories

You'll find plenty of personal accounts online, and some are from real people describing real experiences. Read them as experience, not evidence. Individual stories can't tell you how often something happens, who it won't work for, or what else was going on (rest, rehab, time). They're a reason to have an informed conversation — not a substitute for one.

BPC-157 and TB-500

These two get discussed together because they're studied in complementary repair processes: BPC-157 in blood-vessel growth and gut/tendon models, and TB-4 — the active peptide TB-500 releases — in cell migration and actin regulation. Repair isn't one process; it's several running at once. That's the thinking behind combining peptides, though the combination itself has not been studied as a product. More on TB-500 / TB-4 →

How to get BPC-157 in 2026

Because it isn't an approved drug, BPC-157 is typically accessed through a licensed physician who can evaluate whether it's appropriate for you and where a legitimate, tested product comes from. The two things that matter most: a clinician who actually assesses the injury, and source purity you can verify. Finding a physician →